FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment.
OBJECTIVE: To analyse the distribution of FOXP3+CD25+CD4+ regulatory T cells (Treg) in peripheral blood, synovial fluid and tissue of patients with rheumatic disease during relapse and after local treatment. METHODS: FOXP3 expression was assessed by flow cytometry, immunohistochemistry, immunofluor...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado: |
2009
|
| _version_ | 1826298236883697664 |
|---|---|
| author | Raghavan, S Cao, D Widhe, M Roth, K Herrath, J Engström, M Roncador, G Banham, A Trollmo, C Catrina, A Malmström, V |
| author_facet | Raghavan, S Cao, D Widhe, M Roth, K Herrath, J Engström, M Roncador, G Banham, A Trollmo, C Catrina, A Malmström, V |
| author_sort | Raghavan, S |
| collection | OXFORD |
| description | OBJECTIVE: To analyse the distribution of FOXP3+CD25+CD4+ regulatory T cells (Treg) in peripheral blood, synovial fluid and tissue of patients with rheumatic disease during relapse and after local treatment. METHODS: FOXP3 expression was assessed by flow cytometry, immunohistochemistry, immunofluorescence and real-time polymerase chain reaction (RT-PCR). The functional suppressive capacity of Treg was analysed after co-culture with effector CD4+CD25- T cells through assessment of proliferation and cytokine secretion. RESULTS: It was shown that FOXP3 protein and mRNA expression in synovial fluid T cells was not confined solely to CD25(bright) T cells as seen in blood, but included CD25(intermediate) and even CD25(neg) T cells. Indeed, synovial fluid CD25(high) T cells showed similar suppressive capacity as CD25(bright) T cells, indicating the presence of functional Treg in T cells with lower intensity of CD25. In synovial tissue, FOXP3+ cells were present in low numbers within T-cell infiltrates and decreased further after intra-articular glucocorticosteroid administration, in parallel with the general reduction in inflammation. CONCLUSIONS: Identification of synovial fluid FOXP3+ Treg with varying intensities of CD25 opens up possibilities for thorough characterisation of this important T-cell subset in the inflammatory compartment. However, only scarce synovial membrane expression of FOXP3 was found even in the absence of overt inflammation, suggesting that the synovial membrane is a site that would benefit therapeutically from Treg expansion. |
| first_indexed | 2024-03-07T04:43:47Z |
| format | Journal article |
| id | oxford-uuid:d28f9f0c-b2b5-41f1-8ff6-cf5b5515b5ff |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:43:47Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:d28f9f0c-b2b5-41f1-8ff6-cf5b5515b5ff2022-03-27T08:04:48ZFOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d28f9f0c-b2b5-41f1-8ff6-cf5b5515b5ffEnglishSymplectic Elements at Oxford2009Raghavan, SCao, DWidhe, MRoth, KHerrath, JEngström, MRoncador, GBanham, ATrollmo, CCatrina, AMalmström, V OBJECTIVE: To analyse the distribution of FOXP3+CD25+CD4+ regulatory T cells (Treg) in peripheral blood, synovial fluid and tissue of patients with rheumatic disease during relapse and after local treatment. METHODS: FOXP3 expression was assessed by flow cytometry, immunohistochemistry, immunofluorescence and real-time polymerase chain reaction (RT-PCR). The functional suppressive capacity of Treg was analysed after co-culture with effector CD4+CD25- T cells through assessment of proliferation and cytokine secretion. RESULTS: It was shown that FOXP3 protein and mRNA expression in synovial fluid T cells was not confined solely to CD25(bright) T cells as seen in blood, but included CD25(intermediate) and even CD25(neg) T cells. Indeed, synovial fluid CD25(high) T cells showed similar suppressive capacity as CD25(bright) T cells, indicating the presence of functional Treg in T cells with lower intensity of CD25. In synovial tissue, FOXP3+ cells were present in low numbers within T-cell infiltrates and decreased further after intra-articular glucocorticosteroid administration, in parallel with the general reduction in inflammation. CONCLUSIONS: Identification of synovial fluid FOXP3+ Treg with varying intensities of CD25 opens up possibilities for thorough characterisation of this important T-cell subset in the inflammatory compartment. However, only scarce synovial membrane expression of FOXP3 was found even in the absence of overt inflammation, suggesting that the synovial membrane is a site that would benefit therapeutically from Treg expansion. |
| spellingShingle | Raghavan, S Cao, D Widhe, M Roth, K Herrath, J Engström, M Roncador, G Banham, A Trollmo, C Catrina, A Malmström, V FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. |
| title | FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. |
| title_full | FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. |
| title_fullStr | FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. |
| title_full_unstemmed | FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. |
| title_short | FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. |
| title_sort | foxp3 expression in blood synovial fluid and synovial tissue during inflammatory arthritis and intra articular corticosteroid treatment |
| work_keys_str_mv | AT raghavans foxp3expressioninbloodsynovialfluidandsynovialtissueduringinflammatoryarthritisandintraarticularcorticosteroidtreatment AT caod foxp3expressioninbloodsynovialfluidandsynovialtissueduringinflammatoryarthritisandintraarticularcorticosteroidtreatment AT widhem foxp3expressioninbloodsynovialfluidandsynovialtissueduringinflammatoryarthritisandintraarticularcorticosteroidtreatment AT rothk foxp3expressioninbloodsynovialfluidandsynovialtissueduringinflammatoryarthritisandintraarticularcorticosteroidtreatment AT herrathj foxp3expressioninbloodsynovialfluidandsynovialtissueduringinflammatoryarthritisandintraarticularcorticosteroidtreatment AT engstromm foxp3expressioninbloodsynovialfluidandsynovialtissueduringinflammatoryarthritisandintraarticularcorticosteroidtreatment AT roncadorg foxp3expressioninbloodsynovialfluidandsynovialtissueduringinflammatoryarthritisandintraarticularcorticosteroidtreatment AT banhama foxp3expressioninbloodsynovialfluidandsynovialtissueduringinflammatoryarthritisandintraarticularcorticosteroidtreatment AT trollmoc foxp3expressioninbloodsynovialfluidandsynovialtissueduringinflammatoryarthritisandintraarticularcorticosteroidtreatment AT catrinaa foxp3expressioninbloodsynovialfluidandsynovialtissueduringinflammatoryarthritisandintraarticularcorticosteroidtreatment AT malmstromv foxp3expressioninbloodsynovialfluidandsynovialtissueduringinflammatoryarthritisandintraarticularcorticosteroidtreatment |